LAMEDITECH (462510) Fundamentals 2026 — Revenue Analysis | SniperIQ
LAMEDITECH (462510) is a KR-listed Healthcare company in Medical - Specialties with a market capitalization of ₩24.2B, trading at ₩2750.00 on the KOE. This SniperIQ fundamentals page covers LAMEDITECH's valuation, profitability (net margin -189.3%), revenue (₩7.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is LAMEDITECH's market cap?
LAMEDITECH (462510) has a market capitalization of approximately ₩24.2B, trading at ₩2750.00 on the KOE. Market cap moves with the live share price.
What is LAMEDITECH's P/E ratio?
LAMEDITECH's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is LAMEDITECH?
LAMEDITECH runs a net profit margin of -189.3%, a gross margin of 42.4%, and an operating margin of -193.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does LAMEDITECH generate?
LAMEDITECH reported revenue of ₩7.2B for fiscal year 2025, with net income of -₩11.4B and earnings per share (EPS) of -1299. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does LAMEDITECH pay a dividend?
LAMEDITECH does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is LAMEDITECH financially healthy?
LAMEDITECH carries a debt-to-equity ratio of 1.30x and a current ratio of 1.41x, with a market beta of 0.38. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is LAMEDITECH a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For LAMEDITECH (462510) the key facts are: market cap ₩24.2B, revenue ₩7.2B, 52-week range 2290-9300. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track LAMEDITECH's full fundamentals live
Get LAMEDITECH's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.